Stem Cell Therapy International, Inc. (OTC.BB: SCII) has announced the pre-closing conditions for the merger with Histostem Co. Ltd. will proceed on schedule with an expected close of the merger in January 2010. The shareholders approved changing the company's name to AmStem Corporation and approved an increase in authorized shares. The company has already filed with FINRA for the official name change to AmStem Corporation. AmStem International, Inc., will be the parent company of Histostem and AmStem International, Inc.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
About Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. (OTCBB: SCII) is in the field of regenerative medicine. SCII (soon to have its name changed to AmStem Corporation) is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
